Skip to main content
Journal of Diabetes Science and Technology logoLink to Journal of Diabetes Science and Technology
. 2024 Jul 29;20(1):87–94. doi: 10.1177/19322968241266822

Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans

Jean C Lu 1,2,3, Dale Morrison 1,3, Bella Halim 1,2, Georgina Manos 1,2, Varuni Obeyesekere 2, Brian Kannard 4, Rajiv Shah 4, Kate Wolfe 4, Blake Morrow 4, Ben Pagliuso 4, Bradley Liang 4, Bella Nava 4, Melissa H Lee 1,2, Elif Ekinci 1,3,5, Alicia J Jenkins 1,2,3, Richard J MacIsaac 1,2,3, David N O’Neal 1,2,3,✉
PMCID: PMC11571936  PMID: 39075942

Abstract

Background and aim:

Continuous glucose monitoring systems (CGMs) have been commercially available since 1999. However, automated insulin delivery systems may benefit from real-time inputs in addition to glucose. Continuous multi-analyte sensing platforms will meet this area of potential growth without increasing the burden of additional devices. We aimed to generate pilot data regarding the safety and function of a first-in-human, single-probe glucose/lactate multi-analyte continuous sensor.

Methods:

The investigational glucose/lactate continuous multi-analyte sensor (PercuSense Inc, Valencia, California) was inserted to the upper arms of 16 adults with diabetes, and data were available for analysis from 11 of these participants (seven female; mean [SD] = age 43 years [16]; body mass index [BMI] = 27 kg/m2 [5]). A commercially available Guardian 3 CGM (Medtronic, Northridge, California) was also inserted into the abdomen for comparison. All participants underwent a meal-test followed by an exercise challenge on day 1 and day 4 of wear. Performance was benchmarked against venous blood YSI glucose and lactate values.

Results:

The investigational glucose sensor had an overall mean absolute relative difference (MARD) of 14.5% (median = 11.2%) which improved on day 4 compared with day 1 (13.9% vs 15.2%). The Guardian 3 CGM had an overall MARD of 13.9% (median = 9.4%). The lactate sensor readings within 20/20% and 40/40% of YSI values were 59.7% and 83.1%, respectively.

Conclusions:

Our initial data support safety and functionality of a novel glucose/lactate continuous multi-analyte sensor. Further sensor refinement will improve run-in performance and accuracy.

Keywords: continuous glucose monitoring, continuous lactate monitoring, multi-analyte sensor, feasibility study

Introduction

Continuous Glucose Monitoring (CGM) systems have been commercially available since 1999 and have been of benefit for people with diabetes.1,2 Advances in CGM technology have increased accuracy, reliability, and ease of use enabling CGM data to reliably inform insulin dosing, an essential step in the development of closed-loop (CL) insulin pump systems. 3 More recently, it has been suggested that CL systems may benefit from additional inputs to glucose in real-time.4,5 Lactate is one such analyte of interest. The normal range of lactate in human blood is 0.5 to 2 mmol/L and can increase up to 25 mmol/L with intense exertion as it is a byproduct of anaerobic metabolism. 6 In addition, an increase in blood lactate concentration at rest could be an indicator of medical conditions such as shock, sepsis, ischemia, respiratory failure, or metformin-associated lactic acidosis (MALA).6,7

Simultaneously, it is increasingly recognized that the burden and intrusiveness associated with technology used to optimize glucose levels in people living with diabetes needs to be minimized. 8 The development of a multi-analyte sensing platform would reconcile these 2 requirements, although care must be taken to not burden the user with information overload. Previous trials in animal models demonstrate feasibility of glucose/lactate sensing, 9 but first-in-human studies incorporating a multi-sensing single insertion device are required. We therefore aimed to determine feasibility and acceptability of a novel multi-analyte continuous sensing platform (PercuSense Inc, Valencia, California) in adult people with diabetes.

Methods

Study Design

This was a single-center (St Vincent’s Hospital, Melbourne, Australia), single-arm non-randomized feasibility study involving four-day wear of an investigational single-probe continuous glucose/lactate multi-analyte sensor. All participants wore the investigational sensing platform for four days on their upper arm. The protocol incorporated standardized meal and exercise challenges on days 1 and 4. The trial was approved by the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC 021/23), the trial was registered (ACTRN12623000537651), and each participant provided written informed consent.

Subjects

Participants were eligible if they were aged 18 to 65 years and had type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) with experience with CGM devices. Participants were excluded from the study if they had experienced a severe hypoglycemic episode or diabetic ketoacidosis in the last month. Concurrent major illnesses precluding safe implementation of the study, pregnancy, or adverse skin conditions or tape adhesive intolerances were also exclusion criteria. No patient-identifying- information was transmitted to the device manufacturer, only the raw sensor data.

Description of the Device

The glucose/lactate continuous monitoring system consists of 2 components: the body-worn assembly and the sensor assembly with inserter. The body-worn assembly contains the electrical components, plastic molded housing, and an electric contact for connection to the sensor. The sensor assembly includes the percutaneous sensor probe contained in a plastic housing as well as the trocar and the insertion device used to place the sensor through the skin. Prior to insertion, the two components snap together, loading the spring and insertion mechanism, ready for the device to be inserted subcutaneously when placed on the skin (Figure 1). After transient needle-assisted insertion at 90° to the skin surface, the adhesive patch holds the device in place on the skin, keeping the sensor fixed in place within the subcutaneous tissue. For this study, the site of insertion was standardized to the upper arm.

Figure 1.

Figure 1.

System components. Investigational continuous monitoring system consists of a body-worn assembly and a sensor assembly with the inserter.

The investigational combined glucose and lactate sensors employ a planar two-electrode sensor design with glucose oxidase and lactate oxidase imparting the prerequisite sensitivity and specificity. A two-electrode approach enables crosstalk-free multi-analyte sensing by allowing individual sensor electrode arrays to be placed along the line of symmetry of the minimally invasive implanted probe. The core sensor design uses an architected hydrogel transport layer to limit glucose and lactate flux, thereby eliminating the need for hydrophobic limiting membranes used in commercial CGM products.

The combined glucose and lactate sensor is currently fabricated in a Class 7 cleanroom using a largely dry printing process that allows 50 highly uniform combined glucose and lactate sensors in a single manufacturing lot. The sensors were determined to be safe for implantation after successfully passing biocompatibility testing, in accordance with ISO 10993, as well as having a sterility assurance level of 10−6, in accordance with ISO 11137-2.

The body-worn assembly periodically records the sensor output current. The data are stored in the memory with time-stamps associated with the sensor outputs of the working electrodes along with other diagnostic information including potentiostat voltages and battery voltage. Device data were not available to the participants in real-time. After the study was complete, the data recorded were downloaded via wireless or wired connection with the system using proprietary PercuSense Sensor Utility software to convert the binary data into a human-readable format.

The study was designed as a feasibility study with the first in human assessment of the technology, and thus, a thorough calibration algorithm has not been developed. As such, a simple approach to a universal sensor calibration was taken by doing a retrospective calibration using a least squares error fit of the pooled population sensor signal to the YSI reference values with a 7.5-minute prediction horizon. The prediction horizon was applied to minimize the sensor delay and was calculated based on the sensor signal and the signal’s rate of change. The prediction horizon projected the sensor’s future value while still pairing to the next available YSI measurement for mean absolute relative difference (MARD) calculations. The concept of a universal calibration, where all glucose sensors use the same calibration parameters and all lactate sensors use the same calibration parameters, was explored to simulate how a factory calibration may work in the future.

Study Protocol

Participants were consented and screened to determine whether they were eligible for the study. Those deemed eligible attended the clinical trials center at 7 a.m. in a fasted state during which only water was permitted (day 1). An indwelling venous catheter was inserted for blood collection. An investigational sensor was inserted in the upper arm and a commercially available Guardian 3 (G3) (Medtronic, Northridge, CA) CGM system on the abdomen for the study duration. Participants continued with their usual diabetes care whether that was multiple daily injections (MDI), insulin pump therapy or oral hypoglycemic agents. A standardized meal containing 65 g of carbohydrates was eaten 2 hours post-sensor implantation, and participants on insulin therapy were administered their usual dose of rapid-acting insulin 15 minutes pre-meal. Blood glucose and lactate levels were measured via YSI at time-point 0 minutes, just prior to the meal, and then every 15 minutes for 4 hours. All participants then underwent a 40-minute high-intensity exercise test that aimed to achieve approximately 90% age-predicted heart rate maximum and a subjective rating of perceived exertion of approximately 9 out of 10. During exercise, YSI blood glucose and lactate levels were assessed at 5-minute intervals and then at 10-minute intervals over a 60-minute cool-down period. Blood glucose meter readings were also assessed at time 0 minutes and then every 10 minutes during the exercise testing and every 30 minutes during the cool-down period. Following the testing protocol, participants returned home (Figure 2).

Figure 2.

Figure 2.

Overview of study design. Device insertion occurred on day 1 with exactly the same interventions resulting in glucose and lactate excursions on day 1 and day 4.

Participants continued wearing the investigational sensor at home on days 2 and 3. They were instructed to monitor capillary blood glucose levels at home a minimum of 8 times a day with the Contour Next blood glucose meter (Ascensia Diabetes Care, Basel, Switzerland).

On day 4 of the investigational sensor wear, all participants returned to the study center and underwent an identical meal-test and exercise testing protocol as day 1. The sensor was then removed, and the participant exited the study.

Biochemical Analyses

Reference plasma glucose and lactate concentrations were measured using a glucose and L-lactate analyzer (YSI 2300 STAT Plus Glucose & L-Lactate Analyzer, YSI Life Sciences, Yellow Springs, Ohio). Comparisons were also made to capillary glucose meter measurements (Contour Next [Ascensia Diabetes Care, Basel, Switzerland]).

Data Analyses

The primary objective was to assess glucose/lactate multi-analyte sensor feasibility over a four-day duration as determined by MARD for glucose sensor values compared to reference YSI venous blood glucose values and capillary glucose meter measurements. Percentage values within ±15%, ±20%, ±30%, and ±40% were reported for the lactate sensor against YSI measurements, and consensus error grid analyses were plotted for glucose sensor performance. Estimated sensor delay was calculated by determining the lowest aggregated error upon pairing sensor data with YSI reference values at varying delay times.

Results

Sixteen participants were recruited and 5 excluded from the analysis because of failed sensor insertion (n = 3) or trial of alternate sensor design (n = 2). Data from 11 participants with a full data set of paired YSI and sensor data were analyzed. The clinical characteristics of those participants included in the analysis are summarized in Table 1. All participants had T1DM and ranged in age from 22 to 60 years. Body mass index (BMI) ranged from 18.4 to 32.1 kg/m2, and diabetes duration ranged from 5 to 57 years.

Table 1.

Demographics and Baseline Characteristics of Participants.

Characteristics Mean (SD) Range
Age (years) 42.7 (15.8) 22-60
Sex
 Female N = 7
 Male N = 4
Weight (kg) 78.8 (19.6) 49-111
Height (cm) 170 (10.9) 157-190
Body mass index (kg/m2) 27.0 (4.8) 18.4-32.1
Type of diabetes
 Type 1 N = 11
Duration of diabetes (years) 26.1 (17.8) 5-57
HbA1c (%) 7.2 (0.8) 5.9-8.5

The overall performance of the glucose sensor in the system compared with reference YSI is presented in Table 2. There were a total of 635 matched data pairs (306 on day 1 of sensor wear and 329 on day 4 of sensor wear). The overall MARD was 14.5% (95% confidence interval [CI] = 13.5, 15.5) with day 1 MARD being 15.2% (95% CI = 13.9, 16.4) and day 4 MARD being 13.9% (95% CI = 12.5, 15.3). For comparison, the commercially available G3 sensor had an overall MARD of 13.9% (95% CI = 12.6, 15.2). All values from the investigational glucose sensor fell within zones A and B of the consensus error grid analysis (Figure 3).

Table 2.

Glucose Sensor Performance in Comparison to Reference YSI.

Total MARD (95% CI) Day 1 MARD (95% CI) Day 4 MARD (95% CI)
Investigational sensor 14.5 (13.5, 15.5) 15.2 (13.9, 16.4) 13.9 (12.5, 15.3)
G3 sensor 13.9 (12.6, 15.2) 16.2 (14.2, 18.2) 11.0 (9.6, 12.4)

Figure 3.

Figure 3.

Consensus error grid for investigational glucose sensor and G3 glucose sensor.

When comparing the investigational glucose sensor with capillary glucose meter measurements, a total of 143 matched data pairs were available (69 on day 1 of sensor wear and 74 on day 4 of sensor wear). The overall MARD was 17.4% (95% CI = 15.2, 19.5) with day 1 being 18.8% (95% CI = 15.2, 22.4) and day 4 being 16.0% (95% CI = 13.4, 18.6) (Table 3).

Table 3.

Glucose Sensor Performance in Comparison to Capillary Glucose Meter Measurements.

Total MARD (95% CI) Day 1 MARD (95% CI) Day 4 MARD (95% CI)
Investigational sensor 17.4 (15.2, 19.5) 18.8 (15.2, 22.4) 16.0 (13.4, 18.6)

During the 2 days of in-clinic testing, venous blood lactate levels ranged from 0.35 to 12.40 mmol/L as assessed by YSI. Investigational lactate sensor readings within 15%, 20%, 30%, and 40% of YSI reference for the lactate sensor in the investigational sensor are summarized (Table 4). Across both days of testing, the percentage of data within 20% of YSI reference was 59.7%. This increased from day 1 to day 4 of wear (39.5% and 78.4%, respectively). Percentage of data within 40% of YSI reference was 83.1% (Figure 4).

Table 4.

Lactate Sensor Performance in Comparison to Reference YSI.

Within 15/15% Within 20/20% Within 30/30% Within 40/40%
Overall % 48.2 59.7 73.1 83.1
Day 1 % 29.4 39.5 52.6 67.7
Day 4 % 65.5 78.4 92.1 97.2

Figure 4.

Figure 4.

Representative meal-test and exercise challenge procedure from a single participant (individual profiles for all participants can be found in Supplementary Material).

There was no crosstalk evident between the glucose and lactate sensors. This was evaluated during the in-clinic testing periods when only one analyte was being manipulated. The signal and accuracy of one sensor were not impacted when challenging the other, thus indicating no significant crosstalk between the two sensors. During the meal periods, the lactate signal remained constant and aligned with the YSI reference values. Similarly, during the exercise periods, the glucose continued its same downward trajectory from the meal challenge and aligned with the YSI reference values.

The estimated mean sensor delays when compared with venous YSI reference was 9.5 minutes for the investigational glucose sensor, 7.5 minutes for the investigational lactate sensor, and 8.5 minutes for the G3 sensor. No adverse events were recorded throughout the study.

There were no adverse events such as sensor site irritation or infection, severe hypoglycemia, or diabetic ketoacidosis.

Discussion

This was a first human study demonstrating feasibility of a multi-analyte, single-probe continuous sensor to our best knowledge. There was no crosstalk between the two sensing modalities, which is of particular importance given that both utilized oxidase enzymes, and as such, peroxide from one sensor could diffuse to the other, causing a false signal. Glucose sensor accuracy compared favorably with a commercially available sensor, whereas the lactate sensor, although less accurate, generated clinically meaningful data by clearly delineating lactate trends.

In terms of glucose sensor performance, the investigational sensor was comparable with the commercially available G3 sensor particularly on day 1 of sensor life. The G3 sensor performed better than the investigational sensor on day 4. However, it must be taken into account that direct comparison between the two sensors is limited as they underwent very different calibration methods. The G3 sensor required capillary blood glucose calibration twice a day while the investigational sensor only underwent universal calibration. Furthermore, both glucose sensors demonstrated higher MARDs than those previously reported for commercially available systems.10,11 However, it should be noted that our data were generated under conditions of rapidly changing glucose levels with much smaller number of participants. Overall, MARD was greater on day 1 in comparison with day 4 for both glucose sensors. The prototype nature of the investigational sensor may have contributed, as the manufacturing process currently involves multiple steps requiring manual alignment which may result in manufacturing inconsistencies, limiting the accuracy of universal calibration and also resulting in some failed sensor insertions. These findings are useful in the ongoing development of future iterations of the multi-analyte sensor. Further studies will also focus on longer-term testing of the sensor in line with that of current commercially available CGM systems.

The existing literature for continuous lactate sensors has been limited to short, single-day studies or studies involving microneedle array platforms with limited data regarding accuracy.12-15 As such, the acceptable error margin for lactate sensors is not as clearly defined as for glucose sensors. 16 In this study, the investigational lactate sensor had lower accuracy than either the investigational or commercially available glucose sensors. As real-time insulin dosing decisions are not being made based on lactate levels, the accuracy of lactate readings may be of less importance than for glucose. Rather, certain lactate thresholds have been used as markers for clinical concern. Historically, a normal lactate level usually refers to levels <2 mmol/L,17-19 whereas a level >4 mmol/L is unusual in healthy and non-critically ill patients at rest and has been used as a threshold for predicting the need for hospital admission in the emergency department setting and mortality in hospitalized patients, 17 and lactate >4 mmol/L has historically been used to define the “anaerobic threshold” during exercise. 20 Therefore, in continuous lactate sensing, a high degree of sensor accuracy is less important than in the case of glucose, although the overall trend remains of significant clinical relevance and being able to reliably identify certain lactate thresholds is important. In our study, 100% of YSI lactate readings >4 mmol/L were during exercise or the recovery period. Our investigational lactate sensor demonstrated quite marked improved accuracy on day 4 compared with day 1, and there were some instances on day 1 where the lactate sensor did not detect a clinically significant lactate >4 mmol/L confirmed on YSI. This likely resulted from variance in manufacturing, which limits the accuracy of universal calibration and also may have led to inconsistent sensor warm-up. Also of significance, the time delay of the investigational sensor was similar to that demonstrated with the glucose sensor. Subcutaneous tissue reaction post-insertion may also reduce sensor accuracy.

Formal data on device tolerance were not collected as this was a feasibility study with a prototype sensor. However, anecdotally, the investigational sensor was well tolerated by all participants despite its relatively bulky form factor. Limitations include the short duration of the study, the small participant subset, and no data were available from T2DM subjects. Future studies will examine the performance of the sensor over a longer wear period as well as collecting data regarding device tolerance. Strengths of the study included a rigorous testing protocol that involved two standardized meal-tests and exercise challenges, which generated significant excursions in glucose lactate with 58 reference data points per participant in addition to the at-home period between the two testing days. The study data will be used to refine the processing algorithm and manufacturing process. Refinement of the form factor and sensor design to reduce size as well as improve ease of use with findings from the study is under development with an approximately 50% reduction in form factor size and 2 mm decrease in sensor implant length.

The development of multi-analyte glucose/lactate continuous sensors has possible real-world applications for individuals with diabetes. Closed-loop system algorithms are improving, but there are still certain scenarios whereby they are challenged to maintain optimum glycemia—exercise and severe illness being two notable situations.21,22 Interstitial fluid lactate levels can be used as a marker of both exercise intensity as well as severe illness and therefore may be a valuable additional input to CL systems to adjust insulin dosing. 23 Furthermore, the principle of multi-analyte continuous sensors could be expanded in the future to include other clinically important analytes, such as ketones.

Conclusions

This first-in-human feasibility study demonstrated promising initial data for the investigational continuous glucose/lactate single-probe multi-analyte sensor. There was no crosstalk between the two sensors and the sensors tracked well with the YSI reference under a strenuous testing protocol. Glucose data were also comparable to a current commercially available CGM system. The trial identified key areas for improvement including sensor warm-up as well as manufacturing consistency.

Supplemental Material

sj-docx-1-dst-10.1177_19322968241266822 – Supplemental material for Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans

Supplemental material, sj-docx-1-dst-10.1177_19322968241266822 for Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans by Jean C. Lu, Dale Morrison, Bella Halim, Georgina Manos, Varuni Obeyesekere, Brian Kannard, Rajiv Shah, Kate Wolfe, Blake Morrow, Ben Pagliuso, Bradley Liang, Bella Nava, Melissa H. Lee, Elif Ekinci, Alicia J. Jenkins, Richard J. MacIsaac and David N. O’Neal in Journal of Diabetes Science and Technology

Acknowledgments

The authors thank study participants.

Footnotes

Abbreviations: CGM, continuous glucose monitor; CL, closed loop; MALA, metformin-associated lactic acidosis; MARD, mean absolute relative difference; MDI, multiple daily injections; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: B.K., R.S., K.W., B.M., B.P., B.L., and B.N. are all employees of PercuSense Incorporated. M.H.L. reports speaker honoraria from Medtronic. R.J.M. has received research grants from Novo Nordisk, Servier, Medtronic, The Rebecca Cooper Medical Research Foundation, St Vincent’s Research Foundation, The Juvenile Diabetes Research Foundation, Grey Innovations, The Diabetes Australia Research Trust/Program, and The National Health and Medical Research Council of Australia. He has also received honoraria for lectures from Eli Lilly, Novo Nordisk, Sanofi Aventis, Astra Zeneca, Merck Sharp & Dohme, Novartis, and Boehringer Ingelheim, and has been or is on the advisory boards for Novo Nordisk, Boehringer Ingelheim-Eli Lilly Diabetes Alliance, Astra Zeneca, and Merck Shape & Dohme. Travel support has been supplied by Novo Nordisk, Sanofi, Boehringer Ingelheim, and Astra Zeneca. He has been a principal investigator for industry-sponsored clinical trials run by Novo Nordisk, Sanofi, Bayer, Johnson-Cilag, and AbbiVe. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. E.E. is on advisory boards for Eli Lilly, Sanofi, Ypsomed, and Pfizer and have provided lectures for Eli Lilly, Boehringer, and Sanofi. These monies are directly donated toward diabetes research at E.E.’s institution. E.E.’s institution gets research funding from Eli Lilly, Boehringer, Sanofi, Novo Nordisk, Medtronic, Applied Therapeutics, Endogenex, Pharmasol, and Arrowhead. A.J.J. has received research support from Medtronic, Sanofi, Abbott Laboratories, and Mylan and has served on advisory boards for Medtronic, Sanofi, and Abbott Diabetes Care. D.N.O has received research support from Medtronic, Insulet, Dexcom, Roche, GlySens, BioCapillary, and Endogenex. He is on the advisory boards for Medtronic, Insulet, Abbott, Ypsomed, Novo Nordisk, and Sanofi. He has also received honoraria for lectures from Medtronic, Insulet, Abbott, Novo Nordisk, and Sanofi. The remaining authors have nothing to disclose.

Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The funding was provided by the Helmsley Charitable Trust.

Supplemental Material: Supplemental material for this article is available online.

References

  • 1. Laffel LM, Kanapka LG, Beck RW, et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323(23):2388-2396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Tamborlane WV, Beck RW. Continuous glucose monitoring in type 1 diabetes mellitus. Lancet. 2009;373(9677):1744-1746. [DOI] [PubMed] [Google Scholar]
  • 3. Bekiari E, Kitsios K, Thabit H, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ. 2018;361:k1310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Lee MH, Paldus B, Krishnamurthy B, et al. The clinical case for the integration of a ketone sensor as part of a closed loop insulin pump system. J Diabetes Sci Technol. 2019;13(5):967-973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Alva S, Castorino K, Cho H, Ou J. Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor. J Diabetes Sci Technol. 2021;15(4):768-774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Rathee K, Dhull V, Dhull R, Singh S. Biosensors based on electrochemical lactate detection: a comprehensive review. Biochem Biophys Rep. 2016;5:35-54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. De Backer D, Creteur J, Zhang H, Norrenberg M, Vincent JL. Lactate production by the lungs in acute lung injury. Am J Respir Crit Care Med. 1997;156(4, pt 1):1099-1104. [DOI] [PubMed] [Google Scholar]
  • 8. McAuley SA, Lee MH, Paldus B, et al. Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized, controlled trial. Diabetes Care. 2020;43(12):3024-3033. [DOI] [PubMed] [Google Scholar]
  • 9. Edgley A, Kompa A, et al. Dual Analyte Glucose/Lactate Sensor in Animal Rat Model (Unpublished data). Parkville, VIC, Australia: Department of Medicine, The University of Melbourne; 2022. [Google Scholar]
  • 10. Christiansen MP, Garg SK, Brazg R, et al. Accuracy of a fourth-generation subcutaneous continuous glucose sensor. Diabetes Technol Ther. 2017;19(8):446-456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Marak MC, Calhoun P, Damiano ER, Russell SJ, Ruedy KJ, Beck RW. Testing the real-world accuracy of the Dexcom G6 Pro CGM during the insulin-only bionic pancreas pivotal trial. Diabetes Technol Ther. 2023;25(11):817-821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Ward WK, House JL, Birck J, Anderson EM, Jansen LB. A wire-based dual-analyte sensor for glucose and lactate: in vitro and in vivo evaluation. Diabetes Technol Ther. 2004;6(3):389-401. [DOI] [PubMed] [Google Scholar]
  • 13. Nguyen D, Lawrence MM, Berg H, et al. Transcutaneous flexible sensor for in vivo photonic detection of pH and lactate. ACS Sens. 2022;7(2):441-452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Dror N, Weidling J, White S, et al. Clinical evaluation of a novel subcutaneous lactate monitor. J Clin Monit Comput. 2022;36(2):537-543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Morrison D, Paldus B, Zaharieva D, et al. Kinetics of continuously measured interstitial versus venous lactate following high intensity exercise in adults with type 1 diabetes. Diabetes Technol Ther. 2020;22(S1):A-100. [Google Scholar]
  • 16. Heinemann L, Schoemaker M, Schmelzeisen-Redecker G, et al. Benefits and limitations of MARD as a performance parameter for continuous glucose monitoring in the interstitial space. J Diabetes Sci Technol. 2020;14(1):135-150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Aduen J, Bernstein WK, Khastgir T, et al. The use and clinical importance of a substrate-specific electrode for rapid determination of blood lactate concentrations. JAMA. 1994;272(21):1678-1685. [PubMed] [Google Scholar]
  • 18. Bakker J, Gris P, Coffernils M, Kahn RJ, Vincent JL. Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg. 1996;171(2):221-226. [DOI] [PubMed] [Google Scholar]
  • 19. Bou Chebl R, Jamali S, Mikati N, et al. Relative hyperlactatemia in the emergency department. Front Med (Lausanne). 2020;7:561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Heck H, Mader A, Hess G, Mücke S, Müller R, Hollmann W. Justification of the 4-mmol/l lactate threshold. Int J Sports Med. 1985;6(3):117-130. [DOI] [PubMed] [Google Scholar]
  • 21. Zaharieva DP, Morrison D, Paldus B, Lal RA, Buckingham BA, O’Neal DN. Practical aspects and exercise safety benefits of automated insulin delivery systems in type 1 diabetes. Diabetes Spectr. 2023;36(2):127-136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Leelarathna L, English SW, Thabit H, et al. Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. Crit Care. 2013;17(4):R159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Phillip M, Kowalski A, Battelino T. Type 1 diabetes: from the dream of automated insulin delivery to a fully artificial pancreas. Nat Med. 2024;30(5):1232-1234. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

sj-docx-1-dst-10.1177_19322968241266822 – Supplemental material for Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans

Supplemental material, sj-docx-1-dst-10.1177_19322968241266822 for Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans by Jean C. Lu, Dale Morrison, Bella Halim, Georgina Manos, Varuni Obeyesekere, Brian Kannard, Rajiv Shah, Kate Wolfe, Blake Morrow, Ben Pagliuso, Bradley Liang, Bella Nava, Melissa H. Lee, Elif Ekinci, Alicia J. Jenkins, Richard J. MacIsaac and David N. O’Neal in Journal of Diabetes Science and Technology


Articles from Journal of Diabetes Science and Technology are provided here courtesy of Diabetes Technology Society

RESOURCES